Open Access[18F]FDDNP PET binding predicts change in executive function in a pilot clinical trial of geriatric depression
Author(s) -
Beatrix KrauseSorio,
Prabha Siddarth,
Kelsey T. Laird,
Linda M. Ercoli,
Katherine L. Narr,
Jorge R. Barrio,
Gary W. Small,
Helen Lavretsky
Publication year - 2020
Publication title -
international psychogeriatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.259
H-Index - 96
eISSN - 1741-203X
pISSN - 1041-6102
DOI - 10.1017/s1041610219002047
Subject(s) - escitalopram , memantine , mood , depression (economics) , medicine , oncology , antidepressant , psychology , psychiatry , dementia , disease , hippocampus , macroeconomics , economics
Geriatric depression often presents with memory and cognitive complaints that are associated with increased risk for Alzheimer's disease (AD). In a parent clinical trial of escitalopram combined with memantine or placebo for geriatric depression and subjective memory complaints, we found that memantine improved executive function and delayed recall performance at 12 months (NCT01902004). In this report, we used positron emission tomography (PET) to assess the relationship between in-vivo amyloid and tau brain biomarkers and clinical and cognitive treatment response.